The review was conducted during the committee meeting held on 08.10.2025, where the firm presented its revised trial protocol and supporting data.
In light of the earlier SEC recommendation dated 24.07.2025, the firm presented a revised protocol for the Phase III clinical trial along with a proof of concept (Published retrospective observational study) in support of the new indication applied for.
Abbott India Limited, a major pharmaceutical company known for its gastroenterology and hepatology portfolio, sought approval to evaluate ursodeoxycholic acid for a new use related to liver injury associated with dengue virus infection.
Ursodeoxycholic acid (UDCA), widely used for treating cholestatic liver diseases, gallstone dissolution and certain hepatobiliary disorders, was proposed to be repurposed for managing liver enzyme elevation noted in dengue-affected patients.
After detailed deliberation, the committee opined that:
1. The proposed effect size for the primary endpoint, defined as a difference of 25 IU/L in mean ALT levels between the treated and placebo groups, is not clinically relevant. This concern was amplified by the very broad ALT range at enrolment (~120 to 1000 IU/L), which, according to the committee, would make the proposed difference insufficiently meaningful from a clinical standpoint.
2. The rationale for treating liver injury observed in dengue virus infection was deemed unclear. The committee observed that the elevation of liver enzymes in dengue patients—particularly in the absence of any clinical symptoms or bilirubin increase—is well recognized to improve spontaneously within a short period. Further, the firm did not provide any mechanistic or clinical justification for why ursodeoxycholic acid would be expected to ameliorate such transient enzyme elevations in dengue cases.
Given these reasons, the committee did not recommend the proposed Phase III clinical study. Instead, it advised the firm to first conduct a proof-of-concept study specifically in the indication applied for, to generate robust preliminary evidence before seeking further clinical trial approval.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.